: iStockAnalyst.com Symbols Feed

Biostar Raises $3.6 Million

Fri, 06 Nov 2009 17:26:18 GMT

Biostar Pharmaceuticals has completed a private placement that raised $3.6 million in new capital. Biostar will use the proceeds to complete its new raw materials processing facility. By taking its raw material production in house, Biostar will lower costs and ensure its product quality. Biostar plans to sell excess raw materials to other pharmaceutical companies in the Shaanxi province.[More...]

Bulls Back On Track?

Fri, 06 Nov 2009 16:21:18 GMT

Good morning. With chants of "Dow 10K… Dow 10K" once again rising from the streets at the corner of Broad and Wall yesterday, it is easy to believe that the bulls are back on track and that we'll soon be looking at new highs for the stock market. And when reviewing the data inputs to yesterday's 204 point romp, it is also easy to don the Dow10K hat once again and join in on the celebration.[More...]

Ford's Main Problem: The UAW's Crippling Job Classifications And Work Rules

Fri, 06 Nov 2009 13:52:50 GMT

Ford's 2,215 page 2007 master contract with the UAW 1941 UAW-Ford contract[More...]

Your Kind of Day?

Thu, 05 Nov 2009 19:06:48 GMT

As a rule, I try not to read too terribly much into a "Fed Day" as there is usually a big batch of volatility that may or may not mean much of anything come the dawn of the next day. Maybe, it's just me. Or maybe there are others that find themselves inclined to simply stand aside and watch the nuttiness from the sidelines on "Fed Days." But in any event, the volatility after a Fed announcement, while fun to watch, may not be telling as to what to expect in the future.[More...]

The Dollar-Proof Portfolio

Thu, 05 Nov 2009 17:31:14 GMT

Don't put off this important piece of the financial-planning process.[More...]

What Investors Should Look for In Today’s Fed Statement

Wed, 04 Nov 2009 13:04:24 GMT

In its continuing efforts to nurture the fragile economic recovery, the U.S. Federal Reserve is widely expected to leave interest rates at record lows when it concludes its meeting today (Wednesday).[More...]

Are Discount Brokers Shares Worth Owning?

Wed, 04 Nov 2009 01:28:03 GMT

The third quarter was a favorable one for the longs. Except for a few short-lived, minor pullbacks stock prices moved higher through the quarter. Stock price volatility declined, takeover activity rose, and risk appetite improved to help the S&P gain 15%.[More...]

Technology Rises And Buying Facebook

Tue, 03 Nov 2009 16:54:11 GMT

Technology stocks have done well this year. The Technology Select Sector SPDR (XLK) bottomed out in March and by late October was up more than 60%. Tech has performed better than any other sector year-to-date – up 33.7% as of Friday’s close.[More...]

Buffett Gets His Cheque Book Out

Tue, 03 Nov 2009 16:17:34 GMT

Given the slew of positive economic data Monday you might have been forgiven for expecting a decent rebound in risk assets. There was a rebound of sorts in early New York trading, with the Dow up close to 150 points at one stage.[More...]

Five Ways To Ride The Commodities Bull

Tue, 03 Nov 2009 15:21:07 GMT

Commodity prices have faltered in the last couple of weeks, and much of the “smart money” is saying the boom is over. Don’t believe it.[More...]

Oncothyreon Reports Second Quarter 2009 Financial Results

Wed, 12 Aug 2009 20:49:00 GMT

SEATTLE, Aug. 12 /CNW/ - Oncothyreon Inc. (NASDAQ: ONTY) (TSX: ONY) today reported a net loss of $6.3 million, or $0.30 per basic and diluted share, for the three months ended June 30, 2009, compared with a net loss of $4.9 million, or $0.25 per basic and diluted share, for the comparable period in 2008.
The increase in net loss for the three-month period was primarily the result of this non-cash charge and a decrease in revenue described below, partially offset by decreased operating expenses.
The decrease in net loss for the six-month period was primarily the result of the transfer of manufacturing activities for Stimuvax(R) to Merck KGaA in December 2008, which resulted in a decrease of combined research and development and manufacturing expenses partially offset by a decrease in both contract manufacturing and licensing revenue from collaborative agreements and the non-cash charge discussed above.

: iStockAnalyst.com Symbols Feed

Biostar Raises $3.6 Million

Bulls Back On Track?

Ford's Main Problem: The UAW's Crippling Job Classifications And Work Rules

Your Kind of Day?

The Dollar-Proof Portfolio

What Investors Should Look for In Today’s Fed Statement

Are Discount Brokers Shares Worth Owning?

Technology Rises And Buying Facebook

Buffett Gets His Cheque Book Out

Five Ways To Ride The Commodities Bull

Oncothyreon Reports Second Quarter 2009 Financial Results

Mentor Capital Cancer Immunotherapy Index Improves at a 320% Annualized Rate for Quarter

Mentor Capital Cancer Immunotherapy Index Posts Second 20% Plus Monthly Gain Lead By ImmunoCellular Therapeutics

Oncothyreon to present at BioCentury NewsMakers Conference

Oncothyreon to present at Rodman & Renshaw Global Healthcare Conference

New Cancer Immunotherapy Index Posts 23% Gains Lead By Mentor Capital, Inc. And Oncothyreon

BenchmarkJournal.Com Free Analyst Review for ADSK, SRCL, TFSL, OPWV, TSRA and ONTY

Oncothyreon announces closing of $15.0 million registered direct financing

Form 3 WILLIAMS DOUGLAS E For: Oct 01 (10K)

Form 4 Karan Shashi K. For: Aug 18 (10K)

Form 4 Oncothyreon Inc. For: Jun 12 Filed by: HENNEY CHRISTOPHER S (10K)

Form 4 Jackson Richard L. For: Jun 12 (10K)

Form 4 STOUGHTON W VICKERY For: Jun 12 (10K)

Form 4 SPIEGELMAN DANIEL K For: Jun 12 (10K)

Form 4/A SPIEGELMAN DANIEL K For: Mar 11 (10K)

Form 4/A STOUGHTON W VICKERY For: Mar 11 (10K)

Form 4/A Jackson Richard L. For: Mar 11 (10K)

Form 4/A Christianson Gary For: Mar 11 (10K)